Floatz logo

Letrozole

Male Breast Cancer

Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoSmall moleculePhase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Male Breast Cancer cohort.

Asset / SponsorPhaseRating
Inno-206
National Cancer Institute (NCI)
Phase 2BBB
Cyclophosphamide
Wake Forest University Health Sciences
Phase 2BBB
FILGRASTIM
University of Washington
Phase 2BBB
Irinotecan
University of California, Irvine
Phase 2BBB
Cediranib
University of Chicago
Phase 2BB

View all 50 →

Same molecule, other indications

Letrozole is also rated in:

infertility disorderDormant
BBB
Indicative ·
79 / 100
View asset →
anovulationDormant
BBB
Indicative ·
78 / 100
View asset →
Diabetes MellitusDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →